Investor Presentation: First Nine Months of 2020
31
Investor presentation
First nine months of 2020
Novo Nordisk®
Novo Nordisk's core capabilities provide a competitive advantage
to continue to defeat diabetes
Engineering, formulating,
developing and delivering
protein-based treatments
L
Efficient large-scale
production of proteins
الله
Global commercial reach and
leader in chronic disease care
|.000
५
Deep disease
understanding
0
Today: Oral solutions to
differentiate from
competition
Tomorrow: Expand oral
platforms and transformational
medicines via Novo Nordisk stem
cell platform
balo
Today: The world's
largest producer of
insulin and GLP-1
Tomorrow: Expand capacity by
completion of the US diabetes
API facility and continued
efficiency gains
Today: Global reach and
OzempicⓇ was the fastest
blockbuster in diabetes
Tomorrow: Continued rollout of
injectable diabetes portfolio and
launch of RybelsusⓇ
D
Today: Provide value and
outcomes beyond HbA1c
for diabetes
Tomorrow: Normalise living with
diabetes supported by digital
solutions
API: Active pharmaceutical ingredientView entire presentation